|
|
Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia |
Jianfeng Li1, Yuting Dai1, Liang Wu1, Ming Zhang1, Wen Ouyang1, Jinyan Huang1,2(), Saijuan Chen1,2() |
1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China 2. Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China |
|
|
Abstract B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by genetic alterations with high heterogeneity. Precise subtypes with distinct genomic and/or gene expression patterns have been recently revealed using high-throughput sequencing technology. Most of these profiles are associated with recurrent non-overlapping rearrangements or hotspot point mutations that are analogous to the established subtypes, such as DUX4 rearrangements, MEF2D rearrangements, ZNF384/ZNF362 rearrangements, NUTM1 rearrangements, BCL2/MYC and/or BCL6 rearrangements, ETV6-RUNX1-like gene expression, PAX5alt (diverse PAX5 alterations, including rearrangements, intragenic amplifications, or mutations), and hotspot mutations PAX5 (p.Pro80Arg) with biallelic PAX5 alterations, IKZF1 (p.Asn159Tyr), and ZEB2 (p.His1038Arg). These molecular subtypes could be classified by gene expression patterns with RNA-seq technology. Refined molecular classification greatly improved the treatment strategy. Multiagent therapy regimens, including target inhibitors (e.g., imatinib), immunomodulators, monoclonal antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy, are transforming the clinical practice from chemotherapy drugs to personalized medicine in the field of risk-directed disease management. We provide an update on our knowledge of emerging molecular subtypes and therapeutic targets in BCP-ALL.
|
Keywords
BCP-ALL
subtypes
translocation
aneuploidy
sequence mutations
|
Corresponding Author(s):
Jinyan Huang,Saijuan Chen
|
Just Accepted Date: 27 November 2020
Online First Date: 24 December 2020
Issue Date: 18 June 2021
|
|
1 |
SP Hunger, CG Mullighan. Acute lymphoblastic leukemia in children. N Engl J Med 2015; 373(16): 1541–1552
https://doi.org/10.1056/NEJMra1400972
pmid: 26465987
|
2 |
CH Pui. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia. Front Med 2015; 9(1): 1–9
https://doi.org/10.1007/s11684-015-0381-3
pmid: 25511622
|
3 |
KL Huang, RJ Mashl, Y Wu, DI Ritter, J Wang, C Oh, M Paczkowska, S Reynolds, MA Wyczalkowski, N Oak, AD Scott, M Krassowski, AD Cherniack, KE Houlahan, R Jayasinghe, LB Wang, DC Zhou, D Liu, S Cao, YW Kim, A Koire, JF McMichael, V Hucthagowder, TB Kim, A Hahn, C Wang, MD McLellan, F Al-Mulla, KJ Johnson; Cancer Genome Atlas Research Network, O Lichtarge, PC Boutros, B Raphael, AJ Lazar, W Zhang, MC Wendl, R Govindan, S Jain, D Wheeler, S Kulkarni, JF Dipersio, J Reimand, F Meric-Bernstam, K Chen, I Shmulevich, SE Plon, F Chen, L Ding. Pathogenic germline variants in 10,389 adult cancers. Cell 2018; 173(2): 355–370.e14 PMID: 29625052
https://doi.org/10.1016/j.cell.2018.03.039
|
4 |
ZK Stadler, KA Schrader, J Vijai, ME Robson, K Offit. Cancer genomics and inherited risk. J Clin Oncol 2014; 32(7): 687–698
https://doi.org/10.1200/JCO.2013.49.7271
pmid: 24449244
|
5 |
I Iacobucci, CG Mullighan. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol 2017; 35(9): 975–983
https://doi.org/10.1200/JCO.2016.70.7836
pmid: 28297628
|
6 |
G Genovese, AK Kähler, RE Handsaker, J Lindberg, SA Rose, SF Bakhoum, K Chambert, E Mick, BM Neale, M Fromer, SM Purcell, O Svantesson, M Landén, M Höglund, S Lehmann, SB Gabriel, JL Moran, ES Lander, PF Sullivan, P Sklar, H Grönberg, CM Hultman, SA McCarroll. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371(26): 2477–2487
https://doi.org/10.1056/NEJMoa1409405
pmid: 25426838
|
7 |
J Vijayakrishnan, M Qian, JB Studd, W Yang, B Kinnersley, PJ Law, P Broderick, EA Raetz, J Allan, CH Pui, A Vora, WE Evans, A Moorman, A Yeoh, W Yang, C Li, CR Bartram, CG Mullighan, M Zimmerman, SP Hunger, M Schrappe, MV Relling, M Stanulla, ML Loh, RS Houlston, JJ Yang. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nat Commun 2019; 10(1): 5348
https://doi.org/10.1038/s41467-019-13069-6
pmid: 31767839
|
8 |
JF Li, YT Dai, H Lilljebjörn, SH Shen, BW Cui, L Bai, YF Liu, MX Qian, Y Kubota, H Kiyoi, I Matsumura, Y Miyazaki, L Olsson, AM Tan, H Ariffin, J Chen, J Takita, T Yasuda, H Mano, B Johansson, JJ Yang, AE Yeoh, F Hayakawa, Z Chen, CH Pui, T Fioretos, SJ Chen, JY Huang. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci USA 2018; 115(50): E11711–E11720
https://doi.org/10.1073/pnas.1814397115
pmid: 30487223
|
9 |
Z Gu, ML Churchman, KG Roberts, I Moore, X Zhou, J Nakitandwe, K Hagiwara, S Pelletier, S Gingras, H Berns, D Payne-Turner, A Hill, I Iacobucci, L Shi, S Pounds, C Cheng, D Pei, C Qu, S Newman, M Devidas, Y Dai, SC Reshmi, J Gastier-Foster, EA Raetz, MJ Borowitz, BL Wood, WL Carroll, PA Zweidler-McKay, KR Rabin, LA Mattano, KW Maloney, A Rambaldi, O Spinelli, JP Radich, MD Minden, JM Rowe, S Luger, MR Litzow, MS Tallman, J Racevskis, Y Zhang, R Bhatia, J Kohlschmidt, K Mrózek, CD Bloomfield, W Stock, S Kornblau, HM Kantarjian, M Konopleva, WE Evans, S Jeha, CH Pui, J Yang, E Paietta, JR Downing, MV Relling, J Zhang, ML Loh, SP Hunger, CG Mullighan. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet 2019; 51(2): 296–307
https://doi.org/10.1038/s41588-018-0315-5
pmid: 30643249
|
10 |
CH Pui, JY Tang, JJ Yang, SJ Chen, Z Chen. International collaboration to save children with acute lymphoblastic leukemia. J Glob Oncol 2019; 5(5): 1–2
https://doi.org/10.1200/JGO.19.00010
pmid: 31045474
|
11 |
CH Pui, JJ Yang, N Bhakta, C Rodriguez-Galindo. Global efforts toward the cure of childhood acute lymphoblastic leukaemia. Lancet Child Adolesc Health 2018; 2(6): 440–454
https://doi.org/10.1016/S2352-4642(18)30066-X
pmid: 30169285
|
12 |
DT Teachey, CH Pui. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol 2019; 20(3): e142–e154
https://doi.org/10.1016/S1470-2045(19)30031-2
pmid: 30842058
|
13 |
R Bassan, JP Bourquin, DJ DeAngelo, S Chiaretti. New approaches to the management of adult acute lymphoblastic leukemia. J Clin Oncol 2018; 36(35): 3504−3519 doi:10.1200/JCO.2017.77.3648
pmid: 30240326
|
14 |
B Li, H Li, Y Bai, R Kirschner-Schwabe, JJ Yang, Y Chen, G Lu, G Tzoneva, X Ma, T Wu, W Li, H Lu, L Ding, H Liang, X Huang, M Yang, L Jin, H Kang, S Chen, A Du, S Shen, J Ding, H Chen, J Chen, A von Stackelberg, L Gu, J Zhang, A Ferrando, J Tang, S Wang, BB Zhou. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat Med 2015; 21(6): 563–571
https://doi.org/10.1038/nm.3840
pmid: 25962120
|
15 |
K Ohki, N Kiyokawa, Y Saito, S Hirabayashi, K Nakabayashi, H Ichikawa, Y Momozawa, K Okamura, A Yoshimi, H Ogata-Kawata, H Sakamoto, M Kato, K Fukushima, D Hasegawa, H Fukushima, M Imai, R Kajiwara, T Koike, I Komori, A Matsui, M Mori, K Moriwaki, Y Noguchi, MJ Park, T Ueda, S Yamamoto, K Matsuda, T Yoshida, K Matsumoto, K Hata, M Kubo, Y Matsubara, H Takahashi, T Fukushima, Y Hayashi, K Koh, A Manabe, A Ohara, Tokyo Children’s Cancer Study Group (TCCSG). Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion. Haematologica 2019; 104(1): 128–137
https://doi.org/10.3324/haematol.2017.186320
pmid: 30171027
|
16 |
Z Gu, M Churchman, K Roberts, Y Li, Y Liu, RC Harvey, K McCastlain, SC Reshmi, D Payne-Turner, I Iacobucci, Y Shao, IM Chen, M Valentine, D Pei, KL Mungall, AJ Mungall, Y Ma, R Moore, M Marra, E Stonerock, JM Gastier-Foster, M Devidas, Y Dai, B Wood, M Borowitz, EE Larsen, K Maloney, LA Mattano Jr, A Angiolillo, WL Salzer, MJ Burke, F Gianni, O Spinelli, JP Radich, MD Minden, AV Moorman, B Patel, AK Fielding, JM Rowe, SM Luger, R Bhatia, I Aldoss, SJ Forman, J Kohlschmidt, K Mrózek, G Marcucci, CD Bloomfield, W Stock, S Kornblau, HM Kantarjian, M Konopleva, E Paietta, CL Willman, ML Loh, SP Hunger, CG Mullighan. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun 2016; 7: 13331
https://doi.org/10.1038/ncomms13331
pmid: 27824051
|
17 |
H Lilljebjörn, R Henningsson, A Hyrenius-Wittsten, L Olsson, C Orsmark-Pietras, S von Palffy, M Askmyr, M Rissler, M Schrappe, G Cario, A Castor, CJ Pronk, M Behrendtz, F Mitelman, B Johansson, K Paulsson, AK Andersson, M Fontes, T Fioretos. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun 2016; 7(1): 11790
https://doi.org/10.1038/ncomms11790
pmid: 27265895
|
18 |
YF Liu, BY Wang, WN Zhang, JY Huang, BS Li, M Zhang, L Jiang, JF Li, MJ Wang, YJ Dai, ZG Zhang, Q Wang, J Kong, B Chen, YM Zhu, XQ Weng, ZX Shen, JM Li, J Wang, XJ Yan, Y Li, YM Liang, L Liu, XQ Chen, WG Zhang, JS Yan, JD Hu, SH Shen, J Chen, LJ Gu, D Pei, Y Li, G Wu, X Zhou, RB Ren, C Cheng, JJ Yang, KK Wang, SY Wang, J Zhang, JQ Mi, CH Pui, JY Tang, Z Chen, SJ Chen. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine 2016; 8: 173–183
https://doi.org/10.1016/j.ebiom.2016.04.038
pmid: 27428428
|
19 |
DA Arber, A Orazi, R Hasserjian, J Thiele, MJ Borowitz, MM Le Beau, CD Bloomfield, M Cazzola, JW Vardiman. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20): 2391–2405
https://doi.org/10.1182/blood-2016-03-643544
pmid: 27069254
|
20 |
T Yasuda, S Tsuzuki, M Kawazu, F Hayakawa, S Kojima, T Ueno, N Imoto, S Kohsaka, A Kunita, K Doi, T Sakura, T Yujiri, E Kondo, K Fujimaki, Y Ueda, Y Aoyama, S Ohtake, J Takita, E Sai, M Taniwaki, M Kurokawa, S Morishita, M Fukayama, H Kiyoi, Y Miyazaki, T Naoe, H Mano. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 2016; 48(5): 569–574
https://doi.org/10.1038/ng.3535
pmid: 27019113
|
21 |
J Zhang, K McCastlain, H Yoshihara, B Xu, Y Chang, ML Churchman, G Wu, Y Li, L Wei, I Iacobucci, Y Liu, C Qu, J Wen, M Edmonson, D Payne-Turner, KB Kaufmann, SI Takayanagi, E Wienholds, E Waanders, P Ntziachristos, S Bakogianni, J Wang, I Aifantis, KG Roberts, J Ma, G Song, J Easton, HL Mulder, X Chen, S Newman, X Ma, M Rusch, P Gupta, K Boggs, B Vadodaria, J Dalton, Y Liu, ML Valentine, L Ding, C Lu, RS Fulton, L Fulton, Y Tabib, K Ochoa, M Devidas, D Pei, C Cheng, J Yang, WE Evans, MV Relling, CH Pui, S Jeha, RC Harvey, IL Chen, CL Willman, G Marcucci, CD Bloomfield, J Kohlschmidt, K Mrózek, E Paietta, MS Tallman, W Stock, MC Foster, J Racevskis, JM Rowe, S Luger, SM Kornblau, SA Shurtleff, SC Raimondi, ER Mardis, RK Wilson, JE Dick, SP Hunger, ML Loh, JR Downing, CG Mullighan, St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet 2016; 48(12): 1481–1489
https://doi.org/10.1038/ng.3691
pmid: 27776115
|
22 |
M Qian, H Zhang, SK Kham, S Liu, C Jiang, X Zhao, Y Lu, C Goodings, TN Lin, R Zhang, T Moriyama, Z Yin, Z Li, TC Quah, H Ariffin, AM Tan, S Shen, D Bhojwani, S Hu, S Chen, H Zheng, CH Pui, AE Yeoh, JJ Yang. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res 2017; 27(2): 185–195
https://doi.org/10.1101/gr.209163.116
pmid: 27903646
|
23 |
L Holmfeldt, L Wei, E Diaz-Flores, M Walsh, J Zhang, L Ding, D Payne-Turner, M Churchman, A Andersson, SC Chen, K McCastlain, J Becksfort, J Ma, G Wu, SN Patel, SL Heatley, LA Phillips, G Song, J Easton, M Parker, X Chen, M Rusch, K Boggs, B Vadodaria, E Hedlund, C Drenberg, S Baker, D Pei, C Cheng, R Huether, C Lu, RS Fulton, LL Fulton, Y Tabib, DJ Dooling, K Ochoa, M Minden, ID Lewis, LB To, P Marlton, AW Roberts, G Raca, W Stock, G Neale, HG Drexler, RA Dickins, DW Ellison, SA Shurtleff, CH Pui, RC Ribeiro, M Devidas, AJ Carroll, NA Heerema, B Wood, MJ Borowitz, JM Gastier-Foster, SC Raimondi, ER Mardis, RK Wilson, JR Downing, SP Hunger, ML Loh, CG Mullighan. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45(3): 242–252
https://doi.org/10.1038/ng.2532
pmid: 23334668
|
24 |
AK Andersson, J Ma, J Wang, X Chen, AL Gedman, J Dang, J Nakitandwe, L Holmfeldt, M Parker, J Easton, R Huether, R Kriwacki, M Rusch, G Wu, Y Li, H Mulder, S Raimondi, S Pounds, G Kang, L Shi, J Becksfort, P Gupta, D Payne-Turner, B Vadodaria, K Boggs, D Yergeau, J Manne, G Song, M Edmonson, P Nagahawatte, L Wei, C Cheng, D Pei, R Sutton, NC Venn, A Chetcuti, A Rush, D Catchpoole, J Heldrup, T Fioretos, C Lu, L Ding, CH Pui, S Shurtleff, CG Mullighan, ER Mardis, RK Wilson, TA Gruber, J Zhang, JR Downing, St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 2015; 47(4): 330–337
https://doi.org/10.1038/ng.3230
pmid: 25730765
|
25 |
U Fischer, M Forster, A Rinaldi, T Risch, S Sungalee, HJ Warnatz, B Bornhauser, M Gombert, C Kratsch, AM Stütz, M Sultan, J Tchinda, CL Worth, V Amstislavskiy, N Badarinarayan, A Baruchel, T Bartram, G Basso, C Canpolat, G Cario, H Cavé, D Dakaj, M Delorenzi, MP Dobay, C Eckert, E Ellinghaus, S Eugster, V Frismantas, S Ginzel, OA Haas, O Heidenreich, G Hemmrich-Stanisak, K Hezaveh, JI Höll, S Hornhardt, P Husemann, P Kachroo, CP Kratz, G Te Kronnie, B Marovca, F Niggli, AC McHardy, AV Moorman, R Panzer-Grümayer, BS Petersen, B Raeder, M Ralser, P Rosenstiel, D Schäfer, M Schrappe, S Schreiber, M Schütte, B Stade, R Thiele, N von der Weid, A Vora, M Zaliova, L Zhang, T Zichner, M Zimmermann, H Lehrach, A Borkhardt, JP Bourquin, A Franke, JO Korbel, M Stanulla, ML Yaspo. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet 2015; 47(9): 1020–1029
https://doi.org/10.1038/ng.3362
pmid: 26214592
|
26 |
M Zaliova, J Stuchly, L Winkowska, A Musilova, K Fiser, M Slamova, J Starkova, M Vaskova, O Hrusak, L Sramkova, J Stary, J Zuna, J Trka. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort. Haematologica 2019; 104(7): 1396–1406
https://doi.org/10.3324/haematol.2018.204974
pmid: 30630978
|
27 |
CH Pui, KE Nichols, JJ Yang. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol 2019; 16(4): 227–240
https://doi.org/10.1038/s41571-018-0136-6
pmid: 30546053
|
28 |
A Bonaventure, R Harewood, CA Stiller, G Gatta, J Clavel, DC Stefan, H Carreira, D Spika, R Marcos-Gragera, R Peris-Bonet, M Piñeros, M Sant, CE Kuehni, MFG Murphy, MP Coleman, C Allemani, CONCORD Working Group. Worldwide comparison of survival from childhood leukaemia for 1995−2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol 2017; 4(5): e202–e217
https://doi.org/10.1016/S2352-3026(17)30052-2
pmid: 28411119
|
29 |
AE Yeoh, H Ariffin, EL Chai, CS Kwok, YH Chan, K Ponnudurai, D Campana, PL Tan, MY Chan, SK Kham, LA Chong, AM Tan, HP Lin, TC Quah. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol 2012; 30(19): 2384–2392
https://doi.org/10.1200/JCO.2011.40.5936
pmid: 22614971
|
30 |
A Vora, N Goulden, C Mitchell, J Hancock, R Hough, C Rowntree, AV Moorman, R Wade. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol 2014; 15(8): 809–818
https://doi.org/10.1016/S1470-2045(14)70243-8
pmid: 24924991
|
31 |
N Toft, H Birgens, J Abrahamsson, L Griškevičius, H Hallböök, M Heyman, TW Klausen, OG Jónsson, K Palk, K Pruunsild, P Quist-Paulsen, G Vaitkeviciene, K Vettenranta, A Åsberg, TL Frandsen, HV Marquart, HO Madsen, U Norén-Nyström, K Schmiegelow. Results of NOPHO ALL2008 treatment for patients aged 1−45 years with acute lymphoblastic leukemia. Leukemia 2018; 32(3): 606–615
https://doi.org/10.1038/leu.2017.265
pmid: 28819280
|
32 |
CH Pui, D Pei, E Coustan-Smith, S Jeha, C Cheng, WP Bowman, JT Sandlund, RC Ribeiro, JE Rubnitz, H Inaba, D Bhojwani, TA Gruber, WH Leung, JR Downing, WE Evans, MV Relling, D Campana. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol 2015; 16(4): 465–474
https://doi.org/10.1016/S1470-2045(15)70082-3
pmid: 25800893
|
33 |
CH Pui, D Pei, D Campana, C Cheng, JT Sandlund, WP Bowman, MM Hudson, RC Ribeiro, SC Raimondi, S Jeha, SC Howard, D Bhojwani, H Inaba, JE Rubnitz, ML Metzger, TA Gruber, E Coustan-Smith, JR Downing, WH Leung, MV Relling, WE Evans. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 2014; 28(12): 2336–2343
https://doi.org/10.1038/leu.2014.142
pmid: 24781017
|
34 |
AE Place, KE Stevenson, LM Vrooman, MH Harris, SK Hunt, JE O’Brien, JG Supko, BL Asselin, UH Athale, LA Clavell, PD Cole, KM Kelly, C Laverdiere, JM Leclerc, B Michon, MA Schorin, JJ Welch, SE Lipshultz, JL Kutok, TM Blonquist, DS Neuberg, SE Sallan, LB Silverman. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol 2015; 16(16): 1677–1690
https://doi.org/10.1016/S1470-2045(15)00363-0
pmid: 26549586
|
35 |
R Pieters, H de Groot-Kruseman, V Van der Velden, M Fiocco, H van den Berg, E de Bont, RM Egeler, P Hoogerbrugge, G Kaspers, E Van der Schoot, V De Haas, J Van Dongen. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol 2016; 34(22): 2591–2601
https://doi.org/10.1200/JCO.2015.64.6364
pmid: 27269950
|
36 |
SP Hunger, X Lu, M Devidas, BM Camitta, PS Gaynon, NJ Winick, GH Reaman, WL Carroll. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 2012; 30(14): 1663–1669
https://doi.org/10.1200/JCO.2011.37.8018
pmid: 22412151
|
37 |
C Domenech, S Suciu, B De Moerloose, F Mazingue, G Plat, A Ferster, A Uyttebroeck, N Sirvent, P Lutz, K Yakouben, M Munzer, P Röhrlich, D Plantaz, F Millot, P Philippet, N Dastugue, S Girard, H Cavé, Y Benoit, Y Bertrandfor, Children's Leukemia Group (CLG) of European Organisation for Research and Treatment of Cancer (EORTC). Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 2014; 99(7): 1220–1227
https://doi.org/10.3324/haematol.2014.103507
pmid: 24727815
|
38 |
V Conter, CR Bartram, MG Valsecchi, A Schrauder, R Panzer-Grümayer, A Möricke, M Aricò, M Zimmermann, G Mann, G De Rossi, M Stanulla, F Locatelli, G Basso, F Niggli, E Barisone, G Henze, WD Ludwig, OA Haas, G Cazzaniga, R Koehler, D Silvestri, J Bradtke, R Parasole, R Beier, JJ van Dongen, A Biondi, M Schrappe. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115(16): 3206–3214
https://doi.org/10.1182/blood-2009-10-248146
pmid: 20154213
|
39 |
CH Pui, D Campana, D Pei, WP Bowman, JT Sandlund, SC Kaste, RC Ribeiro, JE Rubnitz, SC Raimondi, M Onciu, E Coustan-Smith, LE Kun, S Jeha, C Cheng, SC Howard, V Simmons, A Bayles, ML Metzger, JM Boyett, W Leung, R Handgretinger, JR Downing, WE Evans, MV Relling. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360(26): 2730–2741
https://doi.org/10.1056/NEJMoa0900386
pmid: 19553647
|
40 |
F Pedrosa, E Coustan-Smith, Y Zhou, C Cheng, A Pedrosa, MM Lins, M Pedrosa, N Lucena-Silva, AML Ramos, E Vinhas, GK Rivera, D Campana, RC Ribeiro. Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study. Blood 2020; 135(17): 1458–1466
https://doi.org/10.1182/blood.2019004215
pmid: 32027741
|
41 |
C Eckert, S Groeneveld-Krentz, R Kirschner-Schwabe, N Hagedorn, C Chen-Santel, P Bader, A Borkhardt, G Cario, G Escherich, R Panzer-Grümayer, K Astrahantseff, A Eggert, L Sramkova, A Attarbaschi, JP Bourquin, C Peters, G Henze, A von Stackelberg, ALL-REZ BFM Trial Group. Improving stratification for children with late bone marrow B-cell acute lymphoblastic leukemia relapses with refined response classification and integration of genetics. J Clin Oncol 2019; 37(36): 3493–3506
https://doi.org/10.1200/JCO.19.01694
pmid: 31644328
|
42 |
N Winick, PL Martin, M Devidas, J Shuster, MJ Borowitz, W Paul Bowman, E Larsen, J Pullen, A Carroll, C Willman, SP Hunger, WL Carroll, BM Camitta. Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905. Leukemia 2020; 34(4): 1006–1016
https://doi.org/10.1038/s41375-019-0642-2
pmid: 31728054
|
43 |
N Coccaro, L Anelli, A Zagaria, G Specchia, F Albano. Next-generation sequencing in acute lymphoblastic leukemia. Int J Mol Sci 2019; 20(12): 2929
https://doi.org/10.3390/ijms20122929
pmid: 31208040
|
44 |
ML Churchman, J Low, C Qu, EM Paietta, LH Kasper, Y Chang, D Payne-Turner, MJ Althoff, G Song, SC Chen, J Ma, M Rusch, D McGoldrick, M Edmonson, P Gupta, YD Wang, W Caufield, B Freeman, L Li, JC Panetta, S Baker, YL Yang, KG Roberts, K McCastlain, I Iacobucci, JL Peters, VE Centonze, F Notta, SM Dobson, S Zandi, JE Dick, L Janke, J Peng, K Kodali, V Pagala, J Min, A Mayasundari, RT Williams, CL Willman, J Rowe, S Luger, RA Dickins, RK Guy, T Chen, CG Mullighan. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell 2015; 28(3): 343–356
https://doi.org/10.1016/j.ccell.2015.07.016
pmid: 26321221
|
45 |
S Gu, A Sayad, G Chan, W Yang, Z Lu, C Virtanen, RA Van Etten, BG Neel. SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia 2018; 32(1): 203–213
https://doi.org/10.1038/leu.2017.250
pmid: 28804122
|
46 |
H Pfeifer, G Cazzaniga, VHJ van der Velden, JM Cayuela, B Schäfer, O Spinelli, S Akiki, S Avigad, I Bendit, K Borg, H Cavé, L Elia, SC Reshmi, G Gerrard, S Hayette, M Hermanson, A Juh, T Jurcek, MC Chillón, C Homburg, G Martinelli, V Kairisto, T Lange, T Lion, MC Mueller, F Pane, L Rai, C Damm-Welk, T Sacha, S Schnittger, T Touloumenidou, H Valerhaugen, P Vandenberghe, J Zuna, H Serve, E Herrmann, S Markovic, JJMV Dongen, OG Ottmann. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia 2019; 33(8): 1910–1922
https://doi.org/10.1038/s41375-019-0413-0
pmid: 30858550
|
47 |
M Baccarani, F Castagnetti, G Gugliotta, G Rosti, S Soverini, A Albeer, M Pfirrmann, International BCR-ABL Study Group. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 2019; 33(5): 1173–1183
https://doi.org/10.1038/s41375-018-0341-4
pmid: 30675008
|
48 |
Z Su, F Wu, W Hu, X Liu, S Wu, X Feng, Z Cui, J Yang, Z Wang, H Guan, H Zhao, W Wang, C Zhao, J Peng. Philadelphia chromosome-positive acute myeloid leukemia with masses and osteolytic lesions: finding of 18F-FDG PET/CT. Front Med 2017; 11(3): 440–444
https://doi.org/10.1007/s11684-017-0523-x
pmid: 28550639
|
49 |
CG Mullighan, CB Miller, I Radtke, LA Phillips, J Dalton, J Ma, D White, TP Hughes, MM Le Beau, CH Pui, MV Relling, SA Shurtleff, JR Downing. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453(7191): 110–114
https://doi.org/10.1038/nature06866
pmid: 18408710
|
50 |
Y Lou, Y Ma, C Li, S Suo, H Tong, W Qian, W Mai, H Meng, W Yu, L Mao, J Wei, W Xu, J Jin. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Med 2017; 11(2): 229–238
https://doi.org/10.1007/s11684-017-0506-y
pmid: 28349299
|
51 |
CW Chen, RP Koche, AU Sinha, AJ Deshpande, N Zhu, R Eng, JG Doench, H Xu, SH Chu, J Qi, X Wang, C Delaney, KM Bernt, DE Root, WC Hahn, JE Bradner, SA Armstrong. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med 2015; 21(4): 335–343
https://doi.org/10.1038/nm.3832
pmid: 25822366
|
52 |
C Meyer, J Hofmann, T Burmeister, D Gröger, TS Park, M Emerenciano, M Pombo de Oliveira, A Renneville, P Villarese, E Macintyre, H Cavé, E Clappier, K Mass-Malo, J Zuna, J Trka, E De Braekeleer, M De Braekeleer, SH Oh, G Tsaur, L Fechina, VH van der Velden, JJ van Dongen, E Delabesse, R Binato, ML Silva, A Kustanovich, O Aleinikova, MH Harris, T Lund-Aho, V Juvonen, O Heidenreich, J Vormoor, WW Choi, M Jarosova, A Kolenova, C Bueno, P Menendez, S Wehner, C Eckert, P Talmant, S Tondeur, E Lippert, E Launay, C Henry, P Ballerini, H Lapillone, MB Callanan, JM Cayuela, C Herbaux, G Cazzaniga, PM Kakadiya, S Bohlander, M Ahlmann, JR Choi, P Gameiro, DS Lee, J Krauter, P Cornillet-Lefebvre, G Te Kronnie, BW Schäfer, S Kubetzko, CN Alonso, U zur Stadt, R Sutton, NC Venn, S Izraeli, L Trakhtenbrot, HO Madsen, P Archer, J Hancock, N Cerveira, MR Teixeira, L Lo Nigro, A Möricke, M Stanulla, M Schrappe, L Sedék, T Szczepański, CM Zwaan, EA Coenen, MM van den Heuvel-Eibrink, S Strehl, M Dworzak, R Panzer-Grümayer, T Dingermann, T Klingebiel, R Marschalek. The MLL recombinome of acute leukemias in 2013. Leukemia 2013; 27(11): 2165–2176
https://doi.org/10.1038/leu.2013.135
pmid: 23628958
|
53 |
A Sanjuan-Pla, C Bueno, C Prieto, P Acha, RW Stam, R Marschalek, P Menéndez. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood 2015; 126(25): 2676–2685
https://doi.org/10.1182/blood-2015-09-667378
pmid: 26463423
|
54 |
T Burmeister, N Gökbuget, S Schwartz, L Fischer, D Hubert, A Sindram, D Hoelzer, E Thiel. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica 2010; 95(2): 241–246
https://doi.org/10.3324/haematol.2009.011346
pmid: 19713226
|
55 |
E Papaemmanuil, I Rapado, Y Li, NE Potter, DC Wedge, J Tubio, LB Alexandrov, P Van Loo, SL Cooke, J Marshall, I Martincorena, J Hinton, G Gundem, FW van Delft, S Nik-Zainal, DR Jones, M Ramakrishna, I Titley, L Stebbings, C Leroy, A Menzies, J Gamble, B Robinson, L Mudie, K Raine, S O’Meara, JW Teague, AP Butler, G Cazzaniga, A Biondi, J Zuna, H Kempski, M Muschen, AM Ford, MR Stratton, M Greaves, PJ Campbell. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet 2014; 46(2): 116–125
https://doi.org/10.1038/ng.2874
pmid: 24413735
|
56 |
D Schäfer, M Olsen, D Lähnemann, M Stanulla, R Slany, K Schmiegelow, A Borkhardt, U Fischer. Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening. Blood 2018; 131(7): 821–826
https://doi.org/10.1182/blood-2017-09-808402
pmid: 29311095
|
57 |
T Inaba, WM Roberts, LH Shapiro, KW Jolly, SC Raimondi, SD Smith, AT Look. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992; 257(5069): 531–534
https://doi.org/10.1126/science.1386162
pmid: 1386162
|
58 |
L Harewood, H Robinson, R Harris, MJ Al-Obaidi, GR Jalali, M Martineau, AV Moorman, N Sumption, S Richards, C Mitchell, CJ Harrison. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia 2003; 17(3): 547–553
https://doi.org/10.1038/sj.leu.2402849
pmid: 12646943
|
59 |
CJ Harrison. Blood spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. Blood 2015; 125(9): 1383–1386
https://doi.org/10.1182/blood-2014-08-569228
pmid: 25608562
|
60 |
AV Moorman, H Robinson, C Schwab, SM Richards, J Hancock, CD Mitchell, N Goulden, A Vora, CJ Harrison. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol 2013; 31(27): 3389–3396
https://doi.org/10.1200/JCO.2013.48.9377
pmid: 23940220
|
61 |
AA Wylie, J Schoepfer, W Jahnke, SW Cowan-Jacob, A Loo, P Furet, AL Marzinzik, X Pelle, J Donovan, W Zhu, S Buonamici, AQ Hassan, F Lombardo, V Iyer, M Palmer, G Berellini, S Dodd, S Thohan, H Bitter, S Branford, DM Ross, TP Hughes, L Petruzzelli, KG Vanasse, M Warmuth, F Hofmann, NJ Keen, WR Sellers. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 2017; 543(7647): 733–737
https://doi.org/10.1038/nature21702
pmid: 28329763
|
62 |
L Bullinger, K Döhner, H Döhner. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol 2017; 35(9): 934–946
https://doi.org/10.1200/JCO.2016.71.2208
pmid: 28297624
|
63 |
TB Alexander, Z Gu, I Iacobucci, K Dickerson, JK Choi, B Xu, D Payne-Turner, H Yoshihara, ML Loh, J Horan, B Buldini, G Basso, S Elitzur, V de Haas, CM Zwaan, A Yeoh, D Reinhardt, D Tomizawa, N Kiyokawa, T Lammens, B De Moerloose, D Catchpoole, H Hori, A Moorman, AS Moore, O Hrusak, S Meshinchi, E Orgel, M Devidas, M Borowitz, B Wood, NA Heerema, A Carrol, YL Yang, MA Smith, TM Davidsen, LC Hermida, P Gesuwan, MA Marra, Y Ma, AJ Mungall, RA Moore, SJM Jones, M Valentine, LJ Janke, JE Rubnitz, CH Pui, L Ding, Y Liu, J Zhang, KE Nichols, JR Downing, X Cao, L Shi, S Pounds, S Newman, D Pei, JM Guidry Auvil, DS Gerhard, SP Hunger, H Inaba, CG Mullighan. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 2018; 562(7727): 373–379
https://doi.org/10.1038/s41586-018-0436-0
pmid: 30209392
|
64 |
K Suzuki, Y Okuno, N Kawashima, H Muramatsu, T Okuno, X Wang, S Kataoka, Y Sekiya, M Hamada, N Murakami, D Kojima, K Narita, A Narita, H Sakaguchi, K Sakaguchi, N Yoshida, N Nishio, A Hama, Y Takahashi, K Kudo, K Kato, S Kojima. MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents. J Clin Oncol 2016; 34(28): 3451–3459
https://doi.org/10.1200/JCO.2016.66.5547
pmid: 27507882
|
65 |
L Bastian, MP Schroeder, C Eckert, C Schlee, JO Tanchez, S Kämpf, DL Wagner, V Schulze, K Isaakidis, J Lázaro-Navarro, S Hänzelmann, AR James, A Ekici, T Burmeister, S Schwartz, M Schrappe, M Horstmann, S Vosberg, S Krebs, H Blum, J Hecht, PA Greif, MA Rieger, M Brüggemann, N Gökbuget, M Neumann, CD Baldus. PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. Leukemia 2019; 33(8): 1895–1909; Epub ahead of print
https://doi.org/10.1038/s41375-019-0430-z
pmid: 30842609
|
66 |
BJ McClure, SL Heatley, CH Kok, T Sadras, J An, TP Hughes, RB Lock, D Yeung, R Sutton, DL White. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. Br J Cancer 2018; 118(7): 1000–1004
https://doi.org/10.1038/s41416-018-0022-0
pmid: 29531323
|
67 |
N Ping, H Qiu, Q Wang, H Dai, C Ruan, S Ehrentraut, HG Drexler, RA MacLeod, S Chen. Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion. J Hematol Oncol 2015; 8(1): 100
https://doi.org/10.1186/s13045-015-0197-2
pmid: 26293203
|
68 |
V Prima, SP Hunger. Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia. Leukemia 2007; 21(12): 2470–2475
https://doi.org/10.1038/sj.leu.2404962
pmid: 17898785
|
69 |
L Liu, L Leng, C Liu, C Lu, Y Yuan, L Wu, F Gong, S Zhang, X Wei, M Wang, L Zhao, L Hu, J Wang, H Yang, S Zhu, F Chen, G Lu, Z Shang, G Lin. An integrated chromatin accessibility and transcriptome landscape of human pre-implantation embryos. Nat Commun 2019; 10(1): 364
https://doi.org/10.1038/s41467-018-08244-0
pmid: 30664750
|
70 |
J Wu, J Xu, B Liu, G Yao, P Wang, Z Lin, B Huang, X Wang, T Li, S Shi, N Zhang, F Duan, J Ming, X Zhang, W Niu, W Song, H Jin, Y Guo, S Dai, L Hu, L Fang, Q Wang, Y Li, W Li, J Na, W Xie, Y Sun. Chromatin analysis in human early development reveals epigenetic transition during ZGA. Nature 2018; 557(7704): 256–260
https://doi.org/10.1038/s41586-018-0080-8
pmid: 29720659
|
71 |
X Dong, W Zhang, H Wu, J Huang, M Zhang, P Wang, H Zhang, Z Chen, SJ Chen, G Meng. Structural basis of DUX4/IGH-driven transactivation. Leukemia 2018; 32(6): 1466–1476
https://doi.org/10.1038/s41375-018-0093-1
pmid: 29572508
|
72 |
M Stanulla, E Dagdan, M Zaliova, A Möricke, C Palmi, G Cazzaniga, C Eckert, G Te Kronnie, JP Bourquin, B Bornhauser, R Koehler, CR Bartram, WD Ludwig, K Bleckmann, S Groeneveld-Krentz, D Schewe, SV Junk, L Hinze, N Klein, CP Kratz, A Biondi, A Borkhardt, A Kulozik, MU Muckenthaler, G Basso, MG Valsecchi, S Izraeli, BS Petersen, A Franke, P Dörge, D Steinemann, OA Haas, R Panzer-Grümayer, H Cavé, RS Houlston, G Cario, M Schrappe, M Zimmermann, TRANSCALL Consortium; International BFM Study Group. IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol 2018; 36(12): 1240–1249
https://doi.org/10.1200/JCO.2017.74.3617
pmid: 29498923
|
73 |
M Zaliova, E Potuckova, L Hovorkova, A Musilova, L Winkowska, K Fiser, J Stuchly, E Mejstrikova, J Starkova, J Zuna, J Stary, J Trka. ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity. Haematologica 2019; 104(7): 1407–1416
https://doi.org/10.3324/haematol.2018.204487
pmid: 30630977
|
74 |
L Tian, Y Shao, S Nance, J Dang, B Xu, X Ma, Y Li, B Ju, L Dong, S Newman, X Zhou, P Schreiner, E Tseng, T Hon, M Ashby, C Li, J Easton, TA Gruber, J Zhang. Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia. Nat Commun 2019; 10(1): 2789
https://doi.org/10.1038/s41467-019-10637-8
pmid: 31243274
|
75 |
Q Yang, H She, M Gearing, E Colla, M Lee, JJ Shacka, Z Mao. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 2009; 323(5910): 124–127
https://doi.org/10.1126/science.1166088
pmid: 19119233
|
76 |
D Hirano, F Hayakawa, T Yasuda, N Tange, H Yamamoto, Y Kojima, T Morishita, N Imoto, S Tsuzuki, H Mano, T Naoe, H Kiyoi. Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity. Oncogene 2019; 38(13): 2263–2274
https://doi.org/10.1038/s41388-018-0573-9
pmid: 30478446
|
77 |
B Chen, L Jiang, ML Zhong, JF Li, BS Li, LJ Peng, YT Dai, BW Cui, TQ Yan, WN Zhang, XQ Weng, YY Xie, J Lu, RB Ren, SN Chen, JD Hu, DP Wu, Z Chen, JY Tang, JY Huang, JQ Mi, SJ Chen. Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2018; 115(2): 373–378
https://doi.org/10.1073/pnas.1717125115
pmid: 29279377
|
78 |
I Homminga, R Pieters, AW Langerak, JJ de Rooi, A Stubbs, M Verstegen, M Vuerhard, J Buijs-Gladdines, C Kooi, P Klous, P van Vlierberghe, AA Ferrando, JM Cayuela, B Verhaaf, HB Beverloo, M Horstmann, V de Haas, AS Wiekmeijer, K Pike-Overzet, FJ Staal, W de Laat, J Soulier, F Sigaux, JP Meijerink. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011; 19(4): 484–497
https://doi.org/10.1016/j.ccr.2011.02.008
pmid: 21481790
|
79 |
M Ma, X Wang, J Tang, H Xue, J Chen, C Pan, H Jiang, S Shen. Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia. Front Med 2012; 6(4): 416–420
https://doi.org/10.1007/s11684-012-0224-4
pmid: 23065427
|
80 |
M Seki, S Kimura, T Isobe, K Yoshida, H Ueno, Y Nakajima-Takagi, C Wang, L Lin, A Kon, H Suzuki, Y Shiozawa, K Kataoka, Y Fujii, Y Shiraishi, K Chiba, H Tanaka, T Shimamura, K Masuda, H Kawamoto, K Ohki, M Kato, Y Arakawa, K Koh, R Hanada, H Moritake, M Akiyama, R Kobayashi, T Deguchi, Y Hashii, T Imamura, A Sato, N Kiyokawa, A Oka, Y Hayashi, M Takagi, A Manabe, A Ohara, K Horibe, M Sanada, A Iwama, H Mano, S Miyano, S Ogawa, J Takita. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet 2017; 49(8): 1274–1281
https://doi.org/10.1038/ng.3900
pmid: 28671687
|
81 |
J Zhang, L Ding, L Holmfeldt, G Wu, SL Heatley, D Payne-Turner, J Easton, X Chen, J Wang, M Rusch, C Lu, SC Chen, L Wei, JR Collins-Underwood, J Ma, KG Roberts, SB Pounds, A Ulyanov, J Becksfort, P Gupta, R Huether, RW Kriwacki, M Parker, DJ McGoldrick, D Zhao, D Alford, S Espy, KC Bobba, G Song, D Pei, C Cheng, S Roberts, MI Barbato, D Campana, E Coustan-Smith, SA Shurtleff, SC Raimondi, M Kleppe, J Cools, KA Shimano, ML Hermiston, S Doulatov, K Eppert, E Laurenti, F Notta, JE Dick, G Basso, SP Hunger, ML Loh, M Devidas, B Wood, S Winter, KP Dunsmore, RS Fulton, LL Fulton, X Hong, CC Harris, DJ Dooling, K Ochoa, KJ Johnson, JC Obenauer, WE Evans, CH Pui, CW Naeve, TJ Ley, ER Mardis, RK Wilson, JR Downing, CG Mullighan. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481(7380): 157–163
https://doi.org/10.1038/nature10725
pmid: 22237106
|
82 |
Y Liu, J Easton, Y Shao, J Maciaszek, Z Wang, MR Wilkinson, K McCastlain, M Edmonson, SB Pounds, L Shi, X Zhou, X Ma, E Sioson, Y Li, M Rusch, P Gupta, D Pei, C Cheng, MA Smith, JG Auvil, DS Gerhard, MV Relling, NJ Winick, AJ Carroll, NA Heerema, E Raetz, M Devidas, CL Willman, RC Harvey, WL Carroll, KP Dunsmore, SS Winter, BL Wood, BP Sorrentino, JR Downing, ML Loh, SP Hunger, J Zhang, CG Mullighan. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 2017; 49(8): 1211–1218
https://doi.org/10.1038/ng.3909
pmid: 28671688
|
83 |
V Prima, L Gore, A Caires, T Boomer, M Yoshinari, M Imaizumi, M Varella-Garcia, SP Hunger. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia. Leukemia 2005; 19(5): 806–813
https://doi.org/10.1038/sj.leu.2403684
pmid: 15744350
|
84 |
N Tange, F Hayakawa, T Yasuda, K Odaira, H Yamamoto, D Hirano, T Sakai, S Terakura, S Tsuzuki, H Kiyoi. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion+ ALL cells. Biomed Pharmacother 2020; 128: 110330
https://doi.org/10.1016/j.biopha.2020.110330
pmid: 32504922
|
85 |
A Martini, R La Starza, H Janssen, C Bilhou-Nabera, A Corveleyn, R Somers, A Aventin, R Foà, A Hagemeijer, C Mecucci, P Marynen. Recurrent rearrangement of the Ewing’s sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia. Cancer Res 2002; 62(19): 5408–5412
pmid: 12359745
|
86 |
M Passet, N Boissel, F Sigaux, C Saillard, M Bargetzi, I Ba, X Thomas, C Graux, Y Chalandon, T Leguay, E Lengliné, J Konopacki, S Quentin, E Delabesse, M Lafage-Pochitaloff, C Pastoret, N Grardel, V Asnafi, V Lhéritier, J Soulier, H Dombret, E Clappier, Group for Research on Adult ALL (GRAALL). PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood 2019; 133(3): 280–284 doi:10.1182/blood-2018-10-882142
pmid: 30510083
|
87 |
C Bueno, JR Tejedor, R Bashford-Rogers, L González-Silva, R Valdés-Mas, A Agraz-Doblás, R Díaz de la Guardia, J Ribera, L Zamora, C Bilhou-Nabera, N Abermil, H Guermouche, E Gouache, G Leverger, MF Fraga, AF Fernández, P Ballerini, I Varela, P Menendez. Natural history and cell of origin of TCF3-ZNF384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL. Blood 2019; 134(11): 900–905
https://doi.org/10.1182/blood.2019000893
pmid: 31221673
|
88 |
VJ Savin, M Sharma, J Zhou, D Gennochi, T Fields, R Sharma, ET McCarthy, T Srivastava, J Domen, A Tormo, JF Gauchat. Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J Immunol Res 2015; 2015: 714964
https://doi.org/10.1155/2015/714964
pmid: 26146641
|
89 |
ML Den Boer, M van Slegtenhorst, RX De Menezes, MH Cheok, JG Buijs-Gladdines, ST Peters, LJ Van Zutven, HB Beverloo, PJ Van der Spek, G Escherich, MA Horstmann, GE Janka-Schaub, WA Kamps, WE Evans, R Pieters. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10(2): 125–134
https://doi.org/10.1016/S1470-2045(08)70339-5
pmid: 19138562
|
90 |
KG Roberts, RD Morin, J Zhang, M Hirst, Y Zhao, X Su, SC Chen, D Payne-Turner, ML Churchman, RC Harvey, X Chen, C Kasap, C Yan, J Becksfort, RP Finney, DT Teachey, SL Maude, K Tse, R Moore, S Jones, K Mungall, I Birol, MN Edmonson, Y Hu, KE Buetow, IM Chen, WL Carroll, L Wei, J Ma, M Kleppe, RL Levine, G Garcia-Manero, E Larsen, NP Shah, M Devidas, G Reaman, M Smith, SW Paugh, WE Evans, SA Grupp, S Jeha, CH Pui, DS Gerhard, JR Downing, CL Willman, M Loh, SP Hunger, MA Marra, CG Mullighan. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22(2): 153–166
https://doi.org/10.1016/j.ccr.2012.06.005
pmid: 22897847
|
91 |
KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, K McCastlain, L Ding, C Lu, G Song, J Ma, J Becksfort, M Rusch, SC Chen, J Easton, J Cheng, K Boggs, N Santiago-Morales, I Iacobucci, RS Fulton, J Wen, M Valentine, C Cheng, SW Paugh, M Devidas, IM Chen, S Reshmi, A Smith, E Hedlund, P Gupta, P Nagahawatte, G Wu, X Chen, D Yergeau, B Vadodaria, H Mulder, NJ Winick, EC Larsen, WL Carroll, NA Heerema, AJ Carroll, G Grayson, SK Tasian, AS Moore, F Keller, M Frei-Jones, JA Whitlock, EA Raetz, DL White, TP Hughes, JM Guidry Auvil, MA Smith, G Marcucci, CD Bloomfield, K Mrózek, J Kohlschmidt, W Stock, SM Kornblau, M Konopleva, E Paietta, CH Pui, S Jeha, MV Relling, WE Evans, DS Gerhard, JM Gastier-Foster, E Mardis, RK Wilson, ML Loh, JR Downing, SP Hunger, CL Willman, J Zhang, CG Mullighan. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371(11): 1005–1015
https://doi.org/10.1056/NEJMoa1403088
pmid: 25207766
|
92 |
C Hurtz, GB Wertheim, JP Loftus, D Blumenthal, A Lehman, Y Li, A Bagashev, B Manning, KD Cummins, JK Burkhardt, AE Perl, M Carroll, SK Tasian. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. J Clin Invest 2020; 130(7): 3637–3653
https://doi.org/10.1172/JCI134424
pmid: 32191635
|
93 |
R Sánchez, J Ribera, M Morgades, R Ayala, E Onecha, Y Ruiz-Heredia, A Juárez-Rufián, R de Nicolás, J Sánchez-Pina, S Vives, L Zamora, S Mercadal, R Coll, M Cervera, O García, JM Ribera, J Martínez-López. A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics. Blood Cancer J 2020; 10(4): 43
https://doi.org/10.1038/s41408-020-0308-3
pmid: 32332702
|
94 |
J Tong, RA Flavell, HB Li. RNA m6A modification and its function in diseases. Front Med 2018; 12(4): 481–489
https://doi.org/10.1007/s11684-018-0654-8
pmid: 30097961
|
95 |
E Rheinbay, MM Nielsen, F Abascal, JA Wala, O Shapira, G Tiao, H Hornshøj, JM Hess, RI Juul, Z Lin, L Feuerbach, R Sabarinathan, T Madsen, J Kim, L Mularoni, S Shuai, A Lanzós, C Herrmann, YE Maruvka, C Shen, SB Amin, P Bandopadhayay, J Bertl, KA Boroevich, J Busanovich, J Carlevaro-Fita, D Chakravarty, CWY Chan, D Craft, P Dhingra, K Diamanti, NA Fonseca, A Gonzalez-Perez, Q Guo, MP Hamilton, NJ Haradhvala, C Hong, K Isaev, TA Johnson, M Juul, A Kahles, A Kahraman, Y Kim, J Komorowski, K Kumar, S Kumar, D Lee, KV Lehmann, Y Li, EM Liu, L Lochovsky, K Park, O Pich, ND Roberts, G Saksena, SE Schumacher, N Sidiropoulos, L Sieverling, N Sinnott-Armstrong, C Stewart, D Tamborero, JMC Tubio, HM Umer, L Uusküla-Reimand, C Wadelius, L Wadi, X Yao, CZ Zhang, J Zhang, JE Haber, A Hobolth, M Imielinski, M Kellis, MS Lawrence, C von Mering, H Nakagawa, BJ Raphael, MA Rubin, C Sander, LD Stein, JM Stuart, T Tsunoda, DA Wheeler, R Johnson, J Reimand, M Gerstein, E Khurana, PJ Campbell, N López-Bigas; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Structural Variation Working Group, Weischenfeldt J, Beroukhim R, Martincorena I, Pedersen JS, Getz G; PCAWG Consortium.. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature 2020; 578(7793): 102–111
https://doi.org/10.1038/s41586-020-1965-x
pmid: 32025015
|
96 |
C Calabrese, NR Davidson, D Demircioğlu, NA Fonseca, Y He, A Kahles, KV Lehmann, F Liu, Y Shiraishi, CM Soulette, L Urban, L Greger, S Li, D Liu, MD Perry, Q Xiang, F Zhang, J Zhang, P Bailey, S Erkek, KA Hoadley, Y Hou, MR Huska, H Kilpinen, JO Korbel, MG Marin, J Markowski, T Nandi, Q Pan-Hammarström, CS Pedamallu, R Siebert, SG Stark, H Su, P Tan, SM Waszak, C Yung, S Zhu, P Awadalla, CJ Creighton, M Meyerson, BFF Ouellette, K Wu, H Yang; PCAWG Transcriptome Working Group, Brazma A, Brooks AN, Göke J, Rätsch G, Schwarz RF, Stegle O, Zhang Z; PCAWG Consortium. Genomic basis for RNA alterations in cancer. Nature 2020; 578(7793): 129–136
https://doi.org/10.1038/s41586-020-1970-0
pmid: 32025019
|
97 |
I Miguel-Escalada, S Bonàs-Guarch, I Cebola, J Ponsa-Cobas, J Mendieta-Esteban, G Atla, BM Javierre, DMY Rolando, I Farabella, CC Morgan, J García-Hurtado, A Beucher, I Morán, L Pasquali, M Ramos-Rodríguez, EVR Appel, A Linneberg, AP Gjesing, DR Witte, O Pedersen, N Grarup, P Ravassard, D Torrents, JM Mercader, L Piemonti, T Berney, EJP de Koning, J Kerr-Conte, F Pattou, IO Fedko, L Groop, I Prokopenko, T Hansen, MA Marti-Renom, P Fraser, J Ferrer. Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes. Nat Genet 2019; 51(7): 1137–1148
https://doi.org/10.1038/s41588-019-0457-0
pmid: 31253982
|
98 |
Y Li, ND Roberts, JA Wala, O Shapira, SE Schumacher, K Kumar, E Khurana, S Waszak, JO Korbel, JE Haber, M Imielinski; PCAWG Structural Variation Working Group, Weischenfeldt J, Beroukhim R, Campbell PJ; PCAWG Consortium. Patterns of somatic structural variation in human cancer genomes. Nature 2020; 578(7793): 112–121
https://doi.org/10.1038/s41586-019-1913-9
pmid: 32025012
|
99 |
M Gerstung, C Jolly, I Leshchiner, SC Dentro, S Gonzalez, D Rosebrock, TJ Mitchell, Y Rubanova, P Anur, K Yu, M Tarabichi, A Deshwar, J Wintersinger, K Kleinheinz, I Vázquez-García, K Haase, L Jerman, S Sengupta, G Macintyre, S Malikic, N Donmez, DG Livitz, M Cmero, J Demeulemeester, S Schumacher, Y Fan, X Yao, J Lee, M Schlesner, PC Boutros, DD Bowtell, H Zhu, G Getz, M Imielinski, R Beroukhim, SC Sahinalp, Y Ji, M Peifer, F Markowetz, V Mustonen, K Yuan, W Wang, QD Morris; PCAWG Evolution & Heterogeneity Working Group, Spellman PT, Wedge DC, Van Loo P; PCAWG Consortium. The evolutionary history of 2,658 cancers. Nature 2020; 578(7793): 122–128
https://doi.org/10.1038/s41586-019-1907-7
pmid: 32025013
|
100 |
M Yang, M Vesterlund, I Siavelis, LH Moura-Castro, A Castor, T Fioretos, R Jafari, H Lilljebjörn, DT Odom, L Olsson, N Ravi, EL Woodward, L Harewood, J Lehtiö, K Paulsson. Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia. Nat Commun 2019; 10(1): 1519
https://doi.org/10.1038/s41467-019-09469-3
pmid: 30944321
|
101 |
Z Zhang, Z Pan, Y Ying, Z Xie, S Adhikari, J Phillips, RP Carstens, DL Black, Y Wu, Y Xing. Deep-learning augmented RNA-seq analysis of transcript splicing. Nat Methods 2019; 16(4): 307–310
https://doi.org/10.1038/s41592-019-0351-9
pmid: 30923373
|
102 |
P van Galen, V Hovestadt, MH Wadsworth Ii, TK Hughes, GK Griffin, S Battaglia, JA Verga, J Stephansky, TJ Pastika, J Lombardi Story, GS Pinkus, O Pozdnyakova, I Galinsky, RM Stone, TA Graubert, AK Shalek, JC Aster, AA Lane, BE Bernstein. Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell 2019; 176(6): 1265–1281.e24 PMID: 30827681
https://doi.org/10.1016/j.cell.2019.01.031
|
103 |
Y Liu, C Li, S Shen, X Chen, K Szlachta, MN Edmonson, Y Shao, X Ma, J Hyle, S Wright, B Ju, MC Rusch, Y Liu, B Li, M Macias, L Tian, J Easton, M Qian, JJ Yang, S Hu, AT Look, J Zhang. Discovery of regulatory noncoding variants in individual cancer genomes by using cis-X. Nat Genet 2020; 52(8): 811–818
https://doi.org/10.1038/s41588-020-0659-5
pmid: 32632335
|
104 |
MT Witkowski, I Dolgalev, NA Evensen, C Ma, T Chambers, KG Roberts, S Sreeram, Y Dai, AN Tikhonova, A Lasry, C Qu, D Pei, C Cheng, GA Robbins, J Pierro, S Selvaraj, V Mezzano, M Daves, PJ Lupo, ME Scheurer, CA Loomis, CG Mullighan, W Chen, KR Rabin, A Tsirigos, WL Carroll, I Aifantis. Extensive remodeling of the immune microenvironment in B cell acute lymphoblastic leukemia. Cancer Cell 2020; 37(6): 867–882.e12
https://doi.org/10.1016/j.ccell.2020.04.015
pmid: 32470390
|
105 |
G Rodríguez-Hernández, FV Opitz, P Delgado, C Walter, AF Álvarez-Prado, I González-Herrero, F Auer, U Fischer, S Janssen, C Bartenhagen, J Raboso-Gallego, A Casado-García, A Orfao, O Blanco, D Alonso-López, JL Rivas, SG Tena-Dávila, M Müschen, M Dugas, FJG Criado, MBG Cenador, C Vicente-Dueñas, J Hauer, AR Ramiro, I Sanchez-Garcia, A Borkhardt. Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID. Nat Commun 2019; 10(1): 5563
https://doi.org/10.1038/s41467-019-13570-y
pmid: 31804490
|
106 |
J Dang, L Wei, J de Ridder, X Su, AG Rust, KG Roberts, D Payne-Turner, J Cheng, J Ma, C Qu, G Wu, G Song, RG Huether, B Schulman, L Janke, J Zhang, JR Downing, L van der Weyden, DJ Adams, CG Mullighan. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood 2015; 125(23): 3609–3617
https://doi.org/10.1182/blood-2015-02-626127
pmid: 25855603
|
107 |
N Potter, L Jones, H Blair, S Strehl, CJ Harrison, M Greaves, L Kearney, LJ Russell. Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia. Leukemia 2019; 33(4): 893–904
https://doi.org/10.1038/s41375-018-0297-4
pmid: 30487598
|
108 |
CG Mullighan, S Goorha, I Radtke, CB Miller, E Coustan-Smith, JD Dalton, K Girtman, S Mathew, J Ma, SB Pounds, X Su, CH Pui, MV Relling, WE Evans, SA Shurtleff, JR Downing. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446(7137): 758–764
https://doi.org/10.1038/nature05690
pmid: 17344859
|
109 |
ML Churchman, M Qian, G Te Kronnie, R Zhang, W Yang, H Zhang, T Lana, P Tedrick, R Baskin, K Verbist, JL Peters, M Devidas, E Larsen, IM Moore, Z Gu, C Qu, H Yoshihara, SN Porter, SM Pruett-Miller, G Wu, E Raetz, PL Martin, WP Bowman, N Winick, E Mardis, R Fulton, M Stanulla, WE Evans, MV Relling, CH Pui, SP Hunger, ML Loh, R Handgretinger, KE Nichols, JJ Yang, CG Mullighan. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell 2018; 33(5): 937–948.e8 PMID: 29681510
https://doi.org/DOI: 10.1016/j.ccell.2018.03.021
|
110 |
AM Schram, MT Chang, P Jonsson, A Drilon. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol 2017; 14(12): 735–748
https://doi.org/10.1038/nrclinonc.2017.127
pmid: 28857077
|
111 |
F Le Loarer, S Watson, G Pierron, VT de Montpreville, S Ballet, N Firmin, A Auguste, D Pissaloux, S Boyault, S Paindavoine, PJ Dechelotte, B Besse, JM Vignaud, M Brevet, E Fadel, W Richer, I Treilleux, J Masliah-Planchon, M Devouassoux-Shisheboran, G Zalcman, Y Allory, F Bourdeaut, F Thivolet-Bejui, D Ranchere-Vince, N Girard, S Lantuejoul, F Galateau-Sallé, JM Coindre, A Leary, O Delattre, JY Blay, F Tirode. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet 2015; 47(10): 1200–1205
https://doi.org/10.1038/ng.3399
pmid: 26343384
|
112 |
C French. NUT midline carcinoma. Nat Rev Cancer 2014; 14(3): 149–150
https://doi.org/10.1038/nrc3659
pmid: 25688404
|
113 |
AA Alekseyenko, EM Walsh, X Wang, AR Grayson, PT Hsi, PV Kharchenko, MI Kuroda, CA French. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev 2015; 29(14): 1507–1523
https://doi.org/10.1101/gad.267583.115
pmid: 26220994
|
114 |
FM Hormann, AQ Hoogkamer, HB Beverloo, A Boeree, I Dingjan, MM Wattel, RW Stam, G Escherich, R Pieters, ML den Boer, JM Boer. NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2. Haematologica 2019; 104(10): e455–e459
https://doi.org/10.3324/haematol.2018.206961
pmid: 30872366
|
115 |
T Pincez, JR Landry, M Roussy, L Jouan, M Bilodeau, L Laramée, F Couture, D Sinnett, P Gendron, J Hébert, L Oligny, A Rouette, TH Tran, BT Wilhelm, H Bittencourt, S Cellot. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia. Genes Chromosomes Cancer 2020; 59(2): 125–130
https://doi.org/10.1002/gcc.22808
pmid: 31515871
|
116 |
L Godfrey, J Kerry, R Thorne, E Repapi, JO Davies, M Tapia, E Ballabio, JR Hughes, H Geng, M Konopleva, TA Milne. MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation. Exp Hematol 2017; 47: 64–75 PMID:27856324
https://doi.org/10.1016/j.exphem.2016.11.003
|
117 |
CE de Bock, S Demeyer, S Degryse, D Verbeke, B Sweron, O Gielen, R Vandepoel, C Vicente, M Vanden Bempt, A Dagklis, E Geerdens, S Bornschein, R Gijsbers, J Soulier, JP Meijerink, M Heinäniemi, S Teppo, M Bouvy-Liivrand, O Lohi, E Radaelli, J Cools. HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development. Cancer Discov 2018; 8(5): 616–631
https://doi.org/10.1158/2159-8290.CD-17-0583
pmid: 29496663
|
118 |
J Limpens, R Stad, C Vos, C de Vlaam, D de Jong, GJ van Ommen, E Schuuring, PM Kluin. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85(9): 2528–2536
https://doi.org/10.1182/blood.V85.9.2528.bloodjournal8592528
pmid: 7727781
|
119 |
G Dölken, G Illerhaus, C Hirt, R Mertelsmann. BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 1996; 14(4): 1333–1344
https://doi.org/10.1200/JCO.1996.14.4.1333
pmid: 8648392
|
120 |
F Schüler, L Dölken, C Hirt, T Kiefer, T Berg, G Fusch, K Weitmann, W Hoffmann, C Fusch, S Janz, CS Rabkin, G Dölken. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer 2009; 124(4): 958–963
https://doi.org/10.1002/ijc.23958
pmid: 19030176
|
121 |
S Roulland, RS Kelly, E Morgado, S Sungalee, P Solal-Celigny, P Colombat, N Jouve, D Palli, V Pala, R Tumino, S Panico, C Sacerdote, JR Quirós, CA Gonzáles, MJ Sánchez, M Dorronsoro, C Navarro, A Barricarte, A Tjønneland, A Olsen, K Overvad, F Canzian, R Kaaks, H Boeing, D Drogan, A Nieters, F Clavel-Chapelon, A Trichopoulou, D Trichopoulos, P Lagiou, HB Bueno-de-Mesquita, PH Peeters, R Vermeulen, G Hallmans, B Melin, S Borgquist, J Carlson, E Lund, E Weiderpass, KT Khaw, N Wareham, TJ Key, RC Travis, P Ferrari, I Romieu, E Riboli, G Salles, P Vineis, B Nadel. t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol 2014; 32(13): 1347–1355
https://doi.org/10.1200/JCO.2013.52.8190
pmid: 24687831
|
122 |
NA Johnson, KJ Savage, O Ludkovski, S Ben-Neriah, R Woods, C Steidl, MJ Dyer, R Siebert, J Kuruvilla, R Klasa, JM Connors, RD Gascoyne, DE Horsman. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114(11): 2273–2279
https://doi.org/10.1182/blood-2009-03-212191
pmid: 19597184
|
123 |
XS Puente, S Beà, R Valdés-Mas, N Villamor, J Gutiérrez-Abril, JI Martín-Subero, M Munar, C Rubio-Pérez, P Jares, M Aymerich, T Baumann, R Beekman, L Belver, A Carrio, G Castellano, G Clot, E Colado, D Colomer, D Costa, J Delgado, A Enjuanes, X Estivill, AA Ferrando, JL Gelpí, B González, S González, M González, M Gut, JM Hernández-Rivas, M López-Guerra, D Martín-García, A Navarro, P Nicolás, M Orozco, AR Payer, M Pinyol, DG Pisano, DA Puente, AC Queirós, V Quesada, CM Romeo-Casabona, C Royo, R Royo, M Rozman, N Russiñol, I Salaverría, K Stamatopoulos, HG Stunnenberg, D Tamborero, MJ Terol, A Valencia, N López-Bigas, D Torrents, I Gut, A López-Guillermo, C López-Otín, E Campo. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526(7574): 519–524
https://doi.org/10.1038/nature14666
pmid: 26200345
|
124 |
N Put, P Meeus, B Chatelain, K Rack, N Boeckx, F Nollet, C Graux, E Van Den Neste, A Janssens, V Madoe, A Van Hoof, C Bilhou-Nabera, I Wlodarska, P Vandenberghe, L Michaux. Translocation t(14;18) is not associated with inferior outcome in chronic lymphocytic leukemia. Leukemia 2009; 23(6): 1201–1204
https://doi.org/10.1038/leu.2009.44
pmid: 19295547
|
125 |
N Niitsu, M Okamoto, I Miura, M Hirano. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009; 23(4): 777–783
https://doi.org/10.1038/leu.2008.344
pmid: 19151788
|
126 |
E Leich, I Salaverria, S Bea, A Zettl, G Wright, V Moreno, RD Gascoyne, WC Chan, RM Braziel, LM Rimsza, DD Weisenburger, J Delabie, ES Jaffe, A Lister, J Fitzgibbon, LM Staudt, EM Hartmann, HK Mueller-Hermelink, E Campo, G Ott, A Rosenwald. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 2009; 114(4): 826–834
https://doi.org/10.1182/blood-2009-01-198580
pmid: 19471018
|
127 |
S Le Gouill, P Talmant, C Touzeau, A Moreau, R Garand, N Juge-Morineau, F Gaillard, T Gastinne, N Milpied, P Moreau, JL Harousseau, H Avet-Loiseau. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92(10): 1335–1342
https://doi.org/10.3324/haematol.11305
pmid: 18024371
|
128 |
Y Guo, K Karube, R Kawano, T Yamaguchi, J Suzumiya, GS Huang, K Ohshima. Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. Leukemia 2005; 19(6): 1058–1063
https://doi.org/10.1038/sj.leu.2403738
pmid: 15815725
|
129 |
A Godon, A Moreau, P Talmant, L Baranger-Papot, F Geneviève, N Milpied, M Zandecki, H Avet-Loiseau. Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients. Leukemia 2003; 17(1): 255–259
https://doi.org/10.1038/sj.leu.2402739
pmid: 12529690
|
130 |
JZ Huang, WG Sanger, TC Greiner, LM Staudt, DD Weisenburger, DL Pickering, JC Lynch, JO Armitage, RA Warnke, AA Alizadeh, IS Lossos, R Levy, WC Chan. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99(7): 2285–2290
https://doi.org/10.1182/blood.V99.7.2285
pmid: 11895757
|
131 |
BH Ye, F Lista, F Lo Coco, DM Knowles, K Offit, RS Chaganti, R Dalla-Favera. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262(5134): 747–750
https://doi.org/10.1126/science.8235596
pmid: 8235596
|
132 |
BW Baron, G Nucifora, N McCabe, R Espinosa 3rd, MM Le Beau, TW McKeithan. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proc Natl Acad Sci USA 1993; 90(11): 5262–5266
https://doi.org/10.1073/pnas.90.11.5262
pmid: 8506375
|
133 |
X Zhao, Y Ren, M Lawlor, BD Shah, PMC Park, T Lwin, X Wang, K Liu, M Wang, J Gao, T Li, M Xu, AS Silva, K Lee, T Zhang, JM Koomen, H Jiang, PR Sudalagunta, MB Meads, F Cheng, C Bi, K Fu, H Fan, WS Dalton, LC Moscinski, KH Shain, EM Sotomayor, GG Wang, NS Gray, JL Cleveland, J Qi, J Tao. BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models. Cancer Cell 2019; 35(5): 752–766.e9 PMID: 31085176
https://doi.org/DOI: 10.1016/j.ccell.2019.04.005
|
134 |
LM Wu, J Wang, A Conidi, C Zhao, H Wang, Z Ford, L Zhang, C Zweier, BG Ayee, P Maurel, A Zwijsen, JR Chan, MP Jankowski, D Huylebroeck, QR Lu. Zeb2 recruits HDAC-NuRD to inhibit Notch and controls Schwann cell differentiation and remyelination. Nat Neurosci 2016; 19(8): 1060–1072
https://doi.org/10.1038/nn.4322
pmid: 27294509
|
135 |
JB Studd, M Yang, Z Li, J Vijayakrishnan, Y Lu, AE Yeoh, K Paulsson, RS Houlston. Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism. Leukemia 2019; 33(1): 1–14
https://doi.org/10.1038/s41375-018-0184-z
pmid: 29977016
|
136 |
Z Li, BJ Abraham, A Berezovskaya, N Farah, Y Liu, T Leon, A Fielding, SH Tan, T Sanda, AS Weintraub, B Li, S Shen, J Zhang, MR Mansour, RA Young, AT Look. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia 2017; 31(10): 2057–2064
https://doi.org/10.1038/leu.2017.75
pmid: 28260788
|
137 |
IM Moya, L Umans, E Maas, PN Pereira, K Beets, A Francis, W Sents, EJ Robertson, CL Mummery, D Huylebroeck, A Zwijsen. Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades. Dev Cell 2012; 22(3): 501–514
https://doi.org/10.1016/j.devcel.2012.01.007
pmid: 22364862
|
138 |
LC Fuentealba, E Eivers, A Ikeda, C Hurtado, H Kuroda, EM Pera, EM De Robertis. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Cell 2007; 131(5): 980–993
https://doi.org/10.1016/j.cell.2007.09.027
pmid: 18045539
|
139 |
Y Bi, D Ehirchiou, TM Kilts, CA Inkson, MC Embree, W Sonoyama, L Li, AI Leet, BM Seo, L Zhang, S Shi, MF Young. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 2007; 13(10): 1219–1227
https://doi.org/10.1038/nm1630
pmid: 17828274
|
140 |
Y Shi, J Massagué. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113(6): 685–700
https://doi.org/10.1016/S0092-8674(03)00432-X
pmid: 12809600
|
141 |
M Zaliova, E Potuckova, J Lukes Jr, L Winkowska, J Starkova, I Janotova, L Sramkova, J Stary, J Zuna, M Stanulla, M Zimmermann, B Bornhauser, JP Bourquin, C Eckert, G Cario, J Trka. Frequency and prognostic impact of ZEB2 H1038 and 1072 mutations in childhood B-other acute lymphoblastic leukemia. Haematologica 2020; [Epub ahead of print] doi: 10.3324/haematol.2020.249094
https://doi.org/10.3324/haematol.2020.249094
pmid: 32499245
|
142 |
CDS Katerndahl, LM Heltemes-Harris, MJL Willette, CM Henzler, S Frietze, R Yang, H Schjerven, KAT Silverstein, LB Ramsey, G Hubbard, AD Wells, RP Kuiper, B Scheijen, FN van Leeuwen, M Müschen, SM Kornblau, MA Farrar. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol 2017; 18(6): 694–704
https://doi.org/10.1038/ni.3716
pmid: 28369050
|
143 |
DD Shao, W Xue, EB Krall, A Bhutkar, F Piccioni, X Wang, AC Schinzel, S Sood, J Rosenbluh, JW Kim, Y Zwang, TM Roberts, DE Root, T Jacks, WC Hahn. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014; 158(1): 171–184
https://doi.org/10.1016/j.cell.2014.06.004
pmid: 24954536
|
144 |
SM Lauberth, M Rauchman. A conserved 12-amino acid motif in Sall1 recruits the nucleosome remodeling and deacetylase corepressor complex. J Biol Chem 2006; 281(33): 23922–23931
https://doi.org/10.1074/jbc.M513461200
pmid: 16707490
|
145 |
NL Miller, C Lawson, EG Kleinschmidt, I Tancioni, S Uryu, DD Schlaepfer. A non-canonical role for Rgnef in promoting integrin-stimulated focal adhesion kinase activation. J Cell Sci 2013; 126(21): 5074–5085
https://doi.org/10.1242/jcs.135509
pmid: 24006257
|
146 |
A Graczyk-Jarzynka, R Zagozdzon, A Muchowicz, M Siernicka, P Juszczynski, M Firczuk. New insights into redox homeostasis as a therapeutic target in B-cell malignancies. Curr Opin Hematol 2017; 24(4): 393–401
https://doi.org/10.1097/MOH.0000000000000351
pmid: 28402987
|
147 |
CC Mason, JS Khorashad, SK Tantravahi, TW Kelley, MS Zabriskie, D Yan, AD Pomicter, KR Reynolds, AM Eiring, Z Kronenberg, RL Sherman, JW Tyner, BK Dalley, KH Dao, M Yandell, BJ Druker, J Gotlib, T O’Hare, MW Deininger. Age-related mutations and chronic myelomonocytic leukemia. Leukemia 2016; 30(4): 906–913
https://doi.org/10.1038/leu.2015.337
pmid: 26648538
|
148 |
D Boutboul, HS Kuehn, Z Van de Wyngaert, JE Niemela, I Callebaut, J Stoddard, C Lenoir, V Barlogis, C Farnarier, F Vely, N Yoshida, S Kojima, H Kanegane, A Hoshino, F Hauck, L Lhermitte, V Asnafi, P Roehrs, S Chen, JW Verbsky, KR Calvo, A Husami, K Zhang, J Roberts, D Amrol, J Sleaseman, AP Hsu, SM Holland, R Marsh, A Fischer, TA Fleisher, C Picard, S Latour, SD Rosenzweig. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. J Clin Invest 2018; 128(7): 3071–3087
https://doi.org/10.1172/JCI98164
pmid: 29889099
|
149 |
M Rusch, J Nakitandwe, S Shurtleff, S Newman, Z Zhang, MN Edmonson, M Parker, Y Jiao, X Ma, Y Liu, J Gu, MF Walsh, J Becksfort, A Thrasher, Y Li, J McMurry, E Hedlund, A Patel, J Easton, D Yergeau, B Vadodaria, RG Tatevossian, S Raimondi, D Hedges, X Chen, K Hagiwara, R McGee, GW Robinson, JM Klco, TA Gruber, DW Ellison, JR Downing, J Zhang. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat Commun 2018; 9(1): 3962
https://doi.org/10.1038/s41467-018-06485-7
pmid: 30262806
|
150 |
Z Li, N Jiang, EH Lim, WHN Chin, Y Lu, KH Chiew, SKY Kham, W Yang, TC Quah, HP Lin, AM Tan, H Ariffin, JJ Yang, AE Yeoh. Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq. Leukemia 2020; 34(9): 2418–2429
https://doi.org/10.1038/s41375-020-0774-4
pmid: 32099036
|
151 |
K Hagiwara, L Ding, MN Edmonson, SV Rice, S Newman, J Easton, J Dai, S Meshinchi, RE Ries, M Rusch, J Zhang. RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. Bioinformatics 2020; 36(5): 1382–1390
pmid: 31593214
|
152 |
L Tian, Y Li, MN Edmonson, X Zhou, S Newman, C McLeod, A Thrasher, Y Liu, B Tang, MC Rusch, J Easton, J Ma, E Davis, A Trull, JR Michael, K Szlachta, C Mullighan, SJ Baker, JR Downing, DW Ellison, J Zhang. CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing data. Genome Biol 2020; 21(1): 126
https://doi.org/10.1186/s13059-020-02043-x
pmid: 32466770
|
153 |
LM Brown, A Lonsdale, A Zhu, NM Davidson, B Schmidt, A Hawkins, E Wallach, M Martin, FM Mechinaud, SL Khaw, RC Bartolo, LEA Ludlow, J Challis, I Brooks, V Petrovic, NC Venn, R Sutton, IJ Majewski, A Oshlack, PG Ekert. The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia. Blood Adv 2020; 4(5): 930–942
https://doi.org/10.1182/bloodadvances.2019001008
pmid: 32150610
|
154 |
K Yizhak, F Aguet, J Kim, JM Hess, K Kübler, J Grimsby, R Frazer, H Zhang, NJ Haradhvala, D Rosebrock, D Livitz, X Li, E Arich-Landkof, N Shoresh, C Stewart, AV Segrè, PA Branton, P Polak, KG Ardlie, G Getz. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science 2019; 364(6444): eaaw0726
https://doi.org/10.1126/science.aaw0726
pmid: 31171663
|
155 |
W Arindrarto, DM Borràs, RAL de Groen, RR van den Berg, IJ Locher, SAME van Diessen, R van der Holst, ED van der Meijden, MW Honders, RH de Leeuw, W Verlaat, I Jedema, WGM Kroes, J Knijnenburg, T van Wezel, JSP Vermaat, PJM Valk, B Janssen, P de Knijff, CAM van Bergen, EB van den Akker, PAC Hoen, SM Kiełbasa, JFJ Laros, M Griffioen, H Veelken. Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing. Leukemia 2020; [Epub ahead of print] doi: 10.1038/s41375-020-0762-8
https://doi.org/10.1038/s41375-020-0762-8
pmid: 32127641
|
156 |
M Gu, M Zwiebel, SH Ong, N Boughton, J Nomdedeu, F Basheer, Y Nannya, PM Quiros, S Ogawa, M Cazzola, R Rad, AP Butler, MS Vijayabaskar, GS Vassiliou. RNAmut: robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing. Haematologica 2020; 105(6): e290–e293
https://doi.org/10.3324/haematol.2019.230821
pmid: 31649132
|
157 |
EO Audemard, P Gendron, A Feghaly, VP Lavallée, J Hébert, G Sauvageau, S Lemieux. Targeted variant detection using unaligned RNA-Seq reads. Life Sci Alliance 2019; 2(4): e201900336
https://doi.org/10.26508/lsa.201900336
pmid: 31427380
|
158 |
S Kosugi, Y Momozawa, X Liu, C Terao, M Kubo, Y Kamatani. Comprehensive evaluation of structural variation detection algorithms for whole genome sequencing. Genome Biol 2019; 20(1): 117
https://doi.org/10.1186/s13059-019-1720-5
pmid: 31159850
|
159 |
C Wang, B Gong, PR Bushel, J Thierry-Mieg, D Thierry-Mieg, J Xu, H Fang, H Hong, J Shen, Z Su, J Meehan, X Li, L Yang, H Li, PP Łabaj, DP Kreil, D Megherbi, S Gaj, F Caiment, J van Delft, J Kleinjans, A Scherer, V Devanarayan, J Wang, Y Yang, HR Qian, LJ Lancashire, M Bessarabova, Y Nikolsky, C Furlanello, M Chierici, D Albanese, G Jurman, S Riccadonna, M Filosi, R Visintainer, KK Zhang, J Li, JH Hsieh, DL Svoboda, JC Fuscoe, Y Deng, L Shi, RS Paules, SS Auerbach, W Tong. The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance. Nat Biotechnol 2014; 32(9): 926–932
https://doi.org/10.1038/nbt.3001
pmid: 25150839
|
160 |
B Li, SW Brady, X Ma, S Shen, Y Zhang, Y Li, K Szlachta, L Dong, Y Liu, F Yang, N Wang, DA Flasch, MA Myers, HL Mulder, L Ding, Y Liu, L Tian, K Hagiwara, K Xu, X Zhou, E Sioson, T Wang, L Yang, J Zhao, H Zhang, Y Shao, H Sun, L Sun, J Cai, HY Sun, TN Lin, L Du, H Li, M Rusch, MN Edmonson, J Easton, X Zhu, J Zhang, C Cheng, BJ Raphael, J Tang, JR Downing, LB Alexandrov, BS Zhou, CH Pui, JJ Yang, J Zhang. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood 2020; 135(1): 41–55
https://doi.org/10.1182/blood.2019002220
pmid: 31697823
|
161 |
X Xiao, P Liu, D Li, Z Xia, P Wang, X Zhang, M Liu, L Liao, B Jiao, R Ren. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. J Hematol Oncol 2020; 13(1): 80
https://doi.org/10.1186/s13045-020-00912-3
pmid: 32552902
|
162 |
I Menzl, T Zhang, A Berger-Becvar, R Grausenburger, G Heller, M Prchal-Murphy, L Edlinger, VM Knab, IZ Uras, E Grundschober, K Bauer, M Roth, A Skucha, Y Liu, JM Hatcher, Y Liang, NP Kwiatkowski, D Fux, A Hoelbl-Kovacic, S Kubicek, JV Melo, P Valent, T Weichhart, F Grebien, J Zuber, NS Gray, V Sexl. A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. Nat Commun 2019; 10(1): 4741
https://doi.org/10.1038/s41467-019-12656-x
pmid: 31628323
|
163 |
SL Khaw, S Suryani, K Evans, J Richmond, A Robbins, RT Kurmasheva, CA Billups, SW Erickson, Y Guo, PJ Houghton, MA Smith, H Carol, AW Roberts, DC Huang, RB Lock. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood 2016; 128(10): 1382–1395
https://doi.org/10.1182/blood-2016-03-707414
pmid: 27343252
|
164 |
EM Stein, G Garcia-Manero, DA Rizzieri, R Tibes, JG Berdeja, MR Savona, M Jongen-Lavrenic, JK Altman, B Thomson, SJ Blakemore, SR Daigle, NJ Waters, AB Suttle, A Clawson, R Pollock, A Krivtsov, SA Armstrong, J DiMartino, E Hedrick, B Löwenberg, MS Tallman. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 2018; 131(24): 2661–2669
https://doi.org/10.1182/blood-2017-12-818948
pmid: 29724899
|
165 |
MC Stubbs, W Kim, M Bariteau, T Davis, S Vempati, J Minehart, M Witkin, J Qi, AV Krivtsov, JE Bradner, AL Kung, SA Armstrong. Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL. Clin Cancer Res 2015; 21(10): 2348–2358
https://doi.org/10.1158/1078-0432.CCR-14-1290
pmid: 25688158
|
166 |
AV Krivtsov, K Evans, JY Gadrey, BK Eschle, C Hatton, HJ Uckelmann, KN Ross, F Perner, SN Olsen, T Pritchard, L McDermott, CD Jones, D Jing, A Braytee, D Chacon, E Earley, BM McKeever, D Claremon, AJ Gifford, HJ Lee, BA Teicher, JE Pimanda, D Beck, JA Perry, MA Smith, GM McGeehan, RB Lock, SA Armstrong. A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell 2019; 36(6): 660–673.e11 PMID: 31821784
https://doi.org/DOI: 10.1016/j.ccell.2019.11.001
|
167 |
Z Ying, XF Huang, X Xiang, Y Liu, X Kang, Y Song, X Guo, H Liu, N Ding, T Zhang, P Duan, Y Lin, W Zheng, X Wang, N Lin, M Tu, Y Xie, C Zhang, W Liu, L Deng, S Gao, L Ping, X Wang, N Zhou, J Zhang, Y Wang, S Lin, M Mamuti, X Yu, L Fang, S Wang, H Song, G Wang, L Jones, J Zhu, SY Chen. A safe and potent anti-CD19 CAR T cell therapy. Nat Med 2019; 25(6): 947–953
https://doi.org/10.1038/s41591-019-0421-7
pmid: 31011207
|
168 |
J Pan, Q Niu, B Deng, S Liu, T Wu, Z Gao, Z Liu, Y Zhang, X Qu, Y Zhang, S Liu, Z Ling, Y Lin, Y Zhao, Y Song, X Tan, Y Zhang, Z Li, Z Yin, B Chen, X Yu, J Yan, Q Zheng, X Zhou, J Gao, AH Chang, X Feng, C Tong. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 2019; 33(12): 2854–2866
https://doi.org/10.1038/s41375-019-0488-7
pmid: 31110217
|
169 |
TJ Fry, NN Shah, RJ Orentas, M Stetler-Stevenson, CM Yuan, S Ramakrishna, P Wolters, S Martin, C Delbrook, B Yates, H Shalabi, TJ Fountaine, JF Shern, RG Majzner, DF Stroncek, M Sabatino, Y Feng, DS Dimitrov, L Zhang, S Nguyen, H Qin, B Dropulic, DW Lee, CL Mackall. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018; 24(1): 20–28
https://doi.org/10.1038/nm.4441
pmid: 29155426
|
170 |
H Kantarjian, A Stein, N Gökbuget, AK Fielding, AC Schuh, JM Ribera, A Wei, H Dombret, R Foà, R Bassan, Ö Arslan, MA Sanz, J Bergeron, F Demirkan, E Lech-Maranda, A Rambaldi, X Thomas, HA Horst, M Brüggemann, W Klapper, BL Wood, A Fleishman, D Nagorsen, C Holland, Z Zimmerman, MS Topp. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017; 376(9): 836–847
https://doi.org/10.1056/NEJMoa1609783
pmid: 28249141
|
171 |
KJ Curran, SP Margossian, NA Kernan, LB Silverman, DA Williams, N Shukla, R Kobos, CJ Forlenza, P Steinherz, S Prockop, F Boulad, B Spitzer, MI Cancio, JJ Boelens, AL Kung, V Szenes, JH Park, CS Sauter, G Heller, X Wang, B Senechal, RJ O’Reilly, I Riviere, M Sadelain, RJ Brentjens. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood 2019; 134(26): 2361–2368
https://doi.org/10.1182/blood.2019001641
pmid: 31650176
|
172 |
M Mohty, J Gautier, F Malard, M Aljurf, A Bazarbachi, C Chabannon, MA Kharfan-Dabaja, BN Savani, H Huang, S Kenderian, A Nagler, MA Perales. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia 2019; 33(12): 2767–2778
https://doi.org/10.1038/s41375-019-0615-5
pmid: 31690821
|
173 |
H Chen, F Wang, P Zhang, Y Zhang, Y Chen, X Fan, X Cao, J Liu, Y Yang, B Wang, B Lei, L Gu, J Bai, L Wei, R Zhang, Q Zhuang, W Zhang, W Zhao, A He. Management of cytokine release syndrome related to CAR-T cell therapy. Front Med 2019; 13(5): 610–617
https://doi.org/10.1007/s11684-019-0714-8
pmid: 31571160
|
174 |
Z Chen. Prospects of immunotherapy for cancer. Front Med 2019; 13(1): 1–2
https://doi.org/10.1007/s11684-019-0691-y
pmid: 30826964
|
175 |
KR Schultz, A Carroll, NA Heerema, WP Bowman, A Aledo, WB Slayton, H Sather, M Devidas, HW Zheng, SM Davies, PS Gaynon, M Trigg, R Rutledge, D Jorstad, N Winick, MJ Borowitz, SP Hunger, WL Carroll, B Camitta, Children’s Oncology Group. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia 2014; 28(7): 1467–1471
https://doi.org/10.1038/leu.2014.30
pmid: 24441288
|
176 |
F Malard, M Mohty. Acute lymphoblastic leukaemia. Lancet 2020; 395(10230): 1146–1162
https://doi.org/10.1016/S0140-6736(19)33018-1
pmid: 32247396
|
177 |
J Mikhael, P Richardson, SZ Usmani, N Raje, W Bensinger, C Karanes, F Campana, D Kanagavel, F Dubin, Q Liu, D Semiond, K Anderson. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood 2019; 134(2): 123–133
https://doi.org/10.1182/blood-2019-02-895193
pmid: 30862646
|
178 |
E Diaz-Flores, EQ Comeaux, KL Kim, E Melnik, K Beckman, KL Davis, K Wu, J Akutagawa, O Bridges, R Marino, M Wohlfeil, BS Braun, CG Mullighan, ML Loh. Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res 2019; 79(9): 2339–2351
https://doi.org/10.1158/0008-5472.CAN-18-0236
pmid: 30862722
|
179 |
D Li, Y Hu, Z Jin, Y Zhai, Y Tan, Y Sun, S Zhu, C Zhao, B Chen, J Zhu, Z Chen, S Chen, J Li, H Liu. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. Leukemia 2018; 32(9): 2012–2016
https://doi.org/10.1038/s41375-018-0212-z
pmid: 30046161
|
180 |
E Kim, C Hurtz, S Koehrer, Z Wang, S Balasubramanian, BY Chang, M Müschen, RE Davis, JA Burger. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood 2017; 129(9): 1155–1165
https://doi.org/10.1182/blood-2016-06-722900
pmid: 28031181
|
181 |
G Tzoneva, CL Dieck, K Oshima, A Ambesi-Impiombato, M Sánchez-Martín, CJ Madubata, H Khiabanian, J Yu, E Waanders, I Iacobucci, ML Sulis, M Kato, K Koh, M Paganin, G Basso, JM Gastier-Foster, ML Loh, R Kirschner-Schwabe, CG Mullighan, R Rabadan, AA Ferrando. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 2018; 553(7689): 511–514
https://doi.org/10.1038/nature25186
pmid: 29342136
|
182 |
K Ohki, H Takahashi, T Fukushima, T Nanmoku, S Kusano, M Mori, Y Nakazawa, Y Yuza, M Migita, H Okuno, A Morimoto, H Yoshino, M Kato, Y Hayashi, A Manabe, A Ohara, D Hasegawa, T Inukai, D Tomizawa, K Koh, N Kiyokawa, Tokyo Children’s Cancer Study Group (TCCSG). Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L04–16. Genes Chromosomes Cancer2020; 59(10): 551–561 PMID: 32368831
https://doi.org/10.1002/gcc.22858
|
183 |
M Greaves. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer 2018; 18(8): 471–484
https://doi.org/10.1038/s41568-018-0015-6
pmid: 29784935
|
184 |
LK Meyer, ML Hermiston. The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities. Cancer Drug Resist 2019; 2:313–325
https://doi.org/10.20517/cdr.2019.11
|
185 |
DD Fang, D Wen, Y Xu. Identification of cancer stem cells provides novel tumor models for drug discovery. Front Med 2012; 6(2): 112–121
https://doi.org/10.1007/s11684-012-0199-1
pmid: 22573222
|
186 |
Z Good, J Sarno, A Jager, N Samusik, N Aghaeepour, EF Simonds, L White, NJ Lacayo, WJ Fantl, G Fazio, G Gaipa, A Biondi, R Tibshirani, SC Bendall, GP Nolan, KL Davis. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nat Med 2018; 24(4): 474–483
https://doi.org/10.1038/nm.4505
pmid: 29505032
|
187 |
Y Tan, H Liu, S Chen. Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse. Front Med 2015; 9(4): 412–420
https://doi.org/10.1007/s11684-015-0423-x
pmid: 26482067
|
188 |
AR James, MP Schroeder, M Neumann, L Bastian, C Eckert, N Gökbuget, JO Tanchez, C Schlee, K Isaakidis, S Schwartz, T Burmeister, A von Stackelberg, MA Rieger, S Göllner, M Horstman, M Schrappe, R Kirschner-Schwabe, M Brüggemann, C Müller-Tidow, H Serve, A Akalin, CD Baldus. Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia. J Hematol Oncol 2019; 12(1): 8
https://doi.org/10.1186/s13045-018-0692-3
pmid: 30642353
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|